The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from normal individuals and patients with other neurological disorders. The test, developed by Power3, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer’s disease.

The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.

The four studies present the capabilities of NuroPro for accurate diagnosis, targeted therapy and drug response monitoring. They involve a total of 154 Alzheimer’s disease and 91 Parkinson’s disease patients, 210 age-matched normal and 173 disease control individuals. The abstracts report the combined results from the clinical validation trials of the NuroPro AD and NuroPro PD tests.

Bosquez, medical director of Power3, said: “To date we have not been successful in treating dementia because of the complexity of the diagnosis. These studies show how the NuroPro AD test can specifically diagnose Alzheimer’s disease and also address patient to patient differences. One size does not fit all.”

Marwan Sabbagh, director of clinical research at Banner Sun Health Research Institute, said: “Treatment of Alzheimer’s disease has a greater chance of success if it is detected in earliest stages. As a neurologist and a clinician I am excited at the potential of having this diagnostic tool to detect Alzheimer’s disease and ultimately producing better outcomes and quality of life for those who suffer from the disease.”